Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma

Metformin Sensitizes EGFR-TKI-Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal

(2014) L. Li et al.   CLINICAL CANCER RESEARCH

EGFR Inhibition Induces Proinflammatory Cytokines via NOX4 in HNSCC

(2013) E. V. M. Fletcher et al.   MOLECULAR CANCER RESEARCH

Axl Mediates Acquired Resistance of Head and Neck Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Erlotinib

(2013) Keith M. Giles et al.   MOLECULAR CANCER THERAPEUTICS

Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck

(2012) A. Argiris et al.   ANNALS OF ONCOLOGY

Interleukin-6 signaling pathway in targeted therapy for cancer

(2012) Yuqi Guo et al.   CANCER TREATMENT REVIEWS

A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

(2012) J. A. de Souza et al.   CLINICAL CANCER RESEARCH

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

(2012) Vincent A Miller et al.   LANCET ONCOLOGY

Overcoming resistance to tyrosine kinase inhibitors: Lessons learned from cancer cells treated with EGFR antagonists

(2011) Brent N. Rexer et al.   CELL CYCLE

IL-6/IL-6 receptor system and its role in physiological and pathological conditions

(2011) Masahiko Mihara et al.   CLINICAL SCIENCE

Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

(2010) H. J. Ross et al.   CLINICAL CANCER RESEARCH

TGF-  IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

(2010) Z. Yao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Humanized Anti-Interleukin-6 Receptor Antibody Suppresses Tumor Angiogenesis and In vivo Growth of Human Oral Squamous Cell Carcinoma

(2009) S. Shinriki et al.   CLINICAL CANCER RESEARCH

Stimulated monocyte IL-6 secretion predicts survival of patients with head and neck squamous cell carcinoma

(2008) John-Helge Heimdal et al.   BMC CANCER

Interleukin-6 predicts recurrence and survival among head and neck cancer patients

(2008) Sonia A. Duffy et al.   CANCER